Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | EPOR | P19235 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12013286 | 0.90 | SMN1; SMN2 (0.40) | SMN1; SMN2LMNAHTTASAH1EPHX2 | |
| SCHEMBL12013289 | 0.88 | SMN1; SMN2 (0.38) | SMN1; SMN2LMNAHTTASAH1EPHX2 | |
| SCHEMBL12013299 | 0.82 | TSHR (0.41) | SMN1; SMN2HTTKDM4ETSHRNAAA | |
| SCHEMBL12013291 | 0.81 | — | — | |
| SCHEMBL12013350 | 0.80 | — | — | |
| SCHEMBL12013273 | 0.77 | TSHR (0.47) | KDM4ETSHR | |
| SCHEMBL12616348 | 0.76 | SMN1; SMN2 (0.42) | SMN1; SMN2LMNAHTTASAH1EPHX2 | |
| SCHEMBL12616615 | 0.74 | SMN1; SMN2 (0.40) | SMN1; SMN2LMNAHTTASAH1EPHX2 | |
| SCHEMBL15062478 | 0.73 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNAHTTASAH1EPHX2 | |
| SCHEMBL12013292 | 0.72 | APP (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252778-B2 | Highly fluorinated oils and surfactants and methods of making and using same | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-08-28 | — | — | US | disclosed |
| US-20090264397-A1 | HIGHLY FLUORINATED OILS AND SURFACTANTS AND METHODS OF MAKING AND USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264397-A1 | HIGHLY FLUORINATED OILS AND SURFACTANTS AND METHODS OF MAKING AND USING SAME | FLOT1, ABCB4, SGMS1 | SMN1; SMN2 2088/4885LMNA 1143/4885HTT 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.